Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLGW) Change in Accured Expenses (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Change in Accured Expenses for 2 consecutive years, with $50000.0 as the latest value for Q4 2017.

  • Quarterly Change in Accured Expenses rose 166.25% to $50000.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2017, up 172.72% year-over-year, with the annual reading at $91025.0 for FY2025, 1.39% up from the prior year.
  • Change in Accured Expenses for Q4 2017 was $50000.0 at Bone Biologics, roughly flat from $50000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $297200.0 in Q1 2016, with the low at -$146082.0 in Q3 2016.